Trial Profile

A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 10 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infliximab (Primary) ; Methotrexate
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms DOSE
Sponsors Merck Sharp & Dohme; Schering-Plough Research Institute

Most Recent Events

29 Jun 2012 Companies added in the association field as reported by EudraCT.
28 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
18 Nov 2010 Planned End Date changed from 1 Feb 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com